Lime Health raises $1M to scale AI app that helps patients understand their doctors
Lime Health, a Quebec-based B Corp, has closed $1M in funding from private investors, Desjardins (through its Startup in Residence programme), and the Business Development Bank of Canada (BDC). The money will accelerate the rollout of Emilia, its AI-powered mobile app that records medical consultations and turns them into clear, structured summaries patients can share with loved ones or other caregivers.
"A medical consultation should never end with a patient leaving without fully understanding what was just said," said Francis Robichaud, founder and chief executive officer of Lime Health.
Available on the App Store and Google Play, Emilia launched in September 2025 and has already been adopted by thousands of users in Canada and internationally. The app records exchanges between patients and healthcare professionals, then generates plain-language summaries — including next steps in care.
Healthcare systems worldwide face mounting pressure on resources, and continuity of care remains a persistent challenge. Studies consistently show patients forget 40–80% of what their doctors tell them. Emilia targets that gap directly.
Most AI tools in healthcare aim to reduce clinicians' workloads. Emilia flips the script — it puts AI at the service of the patient, maximising the value of every word a doctor says for the person who needs it most.
Recording medical conversations raises obvious privacy and consent questions, especially as Lime Health expands across jurisdictions with different data protection rules. Scaling into Europe, the US, and the UK means navigating a patchwork of healthcare regulations.
The $1M raise is also modest. Competing with well-funded health-tech players while entering multiple international markets simultaneously will stretch resources thin.
Lime Health's pivot from a patient experience measurement platform to a consumer-facing AI app marks an ambitious repositioning for an early-stage company, backed by two corporate investors — Desjardins and BDC — with deep roots in Canada's public-sector ecosystem. Whether a $1M round provides enough runway to crack regulated markets in Europe and the US will be the real test of that bet.
Read more: canhealth.com
